Press Release

Date: November 02, 2026 Ref. No.: KDL/SE/063/2026-27 To, To, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, Plot No. C-1, Block G, 25th Floor, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (East) Dalal Street, Mumbai- 400001 Mumbai – 400051 Scrip Code: 543328 NSE Symbol: KRSNAA Dear Sir/Madam, Sub: Press Release – Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the Press Release on the Unaudited (Standalone and Consolidated) Financial Results for the quarter and half year ended September 30, 2026. For Krsnaa Diagnostics Limited Sujoy Sudipta Bose Company Secretary & Compliance Officer Encl: as above KRSNAA DIAGNOSTICS LTD. Q2 FY2027 RESULTS | PRESS RELEASE Krsnaa Records Highest Ever Quarterly Revenue of Rs 2,710 Mn Pune, November 02, 2026: Krsnaa Diagnostics Ltd. (BSE: 543328 | NSE: KRSNAA), one of India’s leading integrated diagnostic service providers, today announced its financial and operating performance for the quarter and half year ended September 30, 2026. Revenue from operations grew 32% YoY to Rs 2,710 million, marking the company’s highest ever quarterly revenue. H1 FY27 Revenue increased 27% to Rs 5,065 million, driven by contributions from newly operationalized projects, continued growth in existing operations and expansion of our retail business. (Rs. Million) Q2 FY2027 Q2 FY2026 H1 FY2027 H1 FY2026 Revenue from Operations 2,710 2,060 5,065 3,990 EBITDA 719 602 1,307 1,126 EBITDA Margin % 27% 29% 26% 28% Profit After Tax (PAT) 246 239 411 445 PAT Margin % 9% 12% 8% 11% NB: The moderation in PAT during H1 FY2027 was primarily attributable to upfront expenditure towards the Rajasthan project, with the associated benefits expected to accrue in the coming quarters. Retail business momentum: Retail revenue grew 35% YoY to Rs 235 million, with patient volumes increasing 45% and test volumes growing 48%. The segment contributed approximately 9% of overall revenue, supported by an asset-light network of franchisees, business associates, referral centres and strategic alliances. Project execution and radiology expansion: Continued focus on stabilising and improving utilisation across PPP projects, including Rajasthan. Radiology operations are supported by over 350 radiologists, with teleradiology capabilities across X-ray, CT and MRI. The Company has 57 NABL-accredited pathology laboratories and 75 NABH-accredited radiology centres. Commenting on the results, Mr. Yash Mutha, Managing Director, said: “Q2 FY27 reflects the continued growth of our diagnostic platform, supported by our established business and contributions from newly operationalized projects. Our focus remains on strengthening our existing PPP presence, capitalizing available opportunity in existing and untapped geographies and focus on accelerating cash business and building retail diagnostics as a complementary growth engine. We are also expanding specialized diagnostic offerings and exploring technology-led opportunities to enhance the reach and efficiency of our services.” Mr. Mitesh Dave, Group Chief Executive Officer, said: “Our focus during the quarter remained on execution and improving utilization across our expanding network. We are seeing encouraging traction in retail, with healthy growth in patient and test volumes. Alongside this, we continue to strengthen our radiology and pathology capabilities in an integrated manner. As our newer projects mature, we remain focused on improving operational efficiency and delivering a better patient experience.” About Krsnaa Diagnostics: Krsnaa Diagnostics Ltd. is a differentiated diagnostic services provider across Radiology and Pathology. The Company operates across 19 states and Union Territories with more than 8,400+ touchpoints nationwide, serving patients through its integrated diagnostic, technology and logistics platform. Its guiding philosophy is “Let’s Do Good…”. Safe Harbour: This release may contain forward-looking statements based on management’s current expectations and beliefs. Actual results may differ materially due to economic, business, regulatory, competitive and other risks. Krsnaa Diagnostics assumes no obligation to update such statements.